Product Description: Meropenem trihydrate (SM 7338 trihydrate) is a carbapenem antibiotic with broad-spectrum antibacterial activity. Meropenem trihydrate has activity against susceptible and resistant N. gonorrhoeae (MIC value of 0.02-0.06 mg/mL), H. influenzae (MIC value of 0.03-0.12 mg/mL), and H. ducreyi (MIC value of 0.015-0.12 mg/mL)[1][2].
Applications: COVID-19-immunoregulation
Formula: C17H31N3O8S
Citations: Antimicrob Agents Chemother. 2018 Jul 27;62(8). pii: e00414-18. /bioRxiv. 2024 May 10./Int J Antimicrob Agents. 2018 Aug;52(2):269-271./Biomed Pharmacother. 2023 Nov 8:115856./Emerg Microbes Infect. 2024 Dec;13(1):2321981./Infect Drug Resist. 2021 Jun 30;14:2499-2507./J Antimicrob Chemother. 2020 Jul 1;75(7):1850-1858./Microbiol Spectr. 2024 Aug 6;12(8):e0397923./Microorganisms. 2024 Mar 13, 12(3), 575./Nano Today. 2024 Dec./Nat Commun. 2022 Mar 2;13(1):1116./Nat Microbiol. 2023 Mar;8(3):410-423./Open Forum Infect Dis. 2023 Jan 27./Proc Natl Acad Sci U S A. 2024 Jan 16;121(3):e2314514121./Spectrochim Acta A Mol Biomol Spectrosc. 2020 Apr 5;230:118066.
References: [1]L Slaney, et al. In-vitro activity of meropenem against Neisseria gonorrhoeae, Haemophilus influenzae and H. ducreyi from Canada and Kenya. J Antimicrob Chemother. 1989 Sep;24 Suppl A:183-6./[2]George G Zhanel, et al. Comparative review of the carbapenems. Drugs. 2007;67(7):1027-52./[3]Umit Ateskan, et al. Deferoxamine and meropenem combination therapy in experimental acute pancreatitis. Pancreas. 2003 Oct;27(3):247-52.
CAS Number: 119478-56-7
Molecular Weight: 437.51
Compound Purity: 99.92
Research Area: Infection; Cancer
Solubility: DMSO : 100 mg/mL (ultrasonic)/H2O : 12.5 mg/mL (ultrasonic)
Target: Antibiotic;Bacterial;Penicillin-binding protein (PBP)
Deutsch
English
